Haemolytic uraemic syndrome is an immune-mediated disease: Role of anti-CD36 antibodies

British Journal of Haematology

Volumn 131, Issue 2, 2005, Pages 247-252

  Rock, Gail ^a   Clark, William ^b   Sternbach, Marion ^c   Kolajova, Maria ^a   McLaine, Peter ^d  

^a UNIVERSITY OF OTTAWA   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

^c ST JOSEPH S HOSPITAL   (Canada)

^d CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

Anti CD36 antibodies; Haemolytic uremic syndrome; Immunoblotting; Molecular mimicry; Verotoxin 2

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTIBODY; CD36 ANTIBODY; CD36 ANTIGEN; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VEROTOXIN; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; AUTOANTIBODY; SHIGA TOXIN; VON WILLEBRAND FACTOR;

ADULT; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY COMPLEX; ANTIGEN ANTIBODY REACTION; ARTICLE; CELL LYSATE; CHILD; CONTROLLED STUDY; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN CELL; IMMUNOPATHOLOGY; MAJOR CLINICAL STUDY; MOLECULAR MIMICRY; MOLECULAR PROBE; PATHOGENESIS; PATHOPHYSIOLOGY; PLASMA; PRIORITY JOURNAL; PROTEIN BLOTTING; PROTEIN DOMAIN; PROTEIN PURIFICATION; PROTEIN STRUCTURE; REACTION ANALYSIS; SEQUENCE HOMOLOGY; THROMBOCYTE AGGREGATION; THROMBOCYTE RELEASE REACTION; BLOOD; CELL CULTURE; ENDOTHELIUM CELL; IMMUNOLOGY; METABOLISM; MICROCIRCULATION; PHYSIOLOGY; SECRETION; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESIVENESS; VASCULAR ENDOTHELIUM;

ADAM PROTEINS; ADENOSINE TRIPHOSPHATE; ADULT; ANTIGEN-ANTIBODY REACTIONS; ANTIGENS, CD36; AUTOANTIBODIES; CELLS, CULTURED; CHILD; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HEMOLYTIC-UREMIC SYNDROME; HUMANS; MICROCIRCULATION; MOLECULAR MIMICRY; PLATELET ACTIVATION; PLATELET ADHESIVENESS; SHIGA TOXINS; VON WILLEBRAND FACTOR;

EID: 32944462499     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05761.x     Document Type: Article

References (20)

1. Barington K.A. Kaersgaard P. ( 1999) A very-high-purity von Willebrand factor preparation containing high-molecular-weight multimers. Vox Sanguinis, 76, 85 89.
2. Clark W.F. Naylor C.D. ( 1999) The role of platelets in progressive glomerulosclerosis: mechanisms for intraglomerular platelet activation and pathogenic consequences. Medical Hypotheses, 28, 51 56.
3. Daviet L. McGregor J.L. ( 1997) Vascular biology of CD36: roles of this new adhesion molecule family in different disease states. Thrombosis and Haemostasis 78, 65 69.
4. Furlan M. Robles R. Galbusera M. Remuzzi G. Kyrle P.A. Brenner B. Krause M. Scharrer I. Aumann V. Mittler U. Solenthaler M. Lämmle B. ( 1998) Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. The New England Journal of Medicine, 339, 1578 1584.
5. Furlan M. Robles R. Morselli B. Sandoz P. Lammie B. ( 1999) Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thrombosis and Haemostasis, 81, 8 13.
6. Gottschall J.L. Elliot W. Lianos E. McFarland J.G. Wolfmeyer K. Aster R.H. ( 1991) Quinine-induced immune thrombocytopenia associated with hemolytic uremic syndrome: a new clinical entity. Blood, 77, 306 310.
7. Greenwalt D.E. Lipsky R.H. Ockenhouse C.F. Ikeda H. Tandon N.N. Jamieson G.A. ( 1992) Membrane glycoprotein CD36: a review of its roles in adherence, signal transduction, and transfusion medicine. Blood, 80, 1105 1115.
8. Griffin P.W. Tauxe R.V. ( 1991) The epidemiology of infections caused by E. coli 0157:H7, other enterohemorrhagic E. coli, and the associated hemolytic uremic syndrome. Epidemiologic Reviews, 13, 60 98.
9. Lingwood C.A. ( 1996) Role of verotoxin receptors in pathogenesis. Trends in Microbiology, 4, 147 153.
10. Moake J.L. Turner N.A. Stathopoulos N.A. Nolasco L.H. Hellums J.D. ( 1986) Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. The Journal of Clinical Investigation, 78, 1456 1461.
11. Rock G. ( 1990) A comparison of two methods for the discrimination of vWF: AG multimers. Thrombosis Research, 57, 817 824.
12. Rock G. Décary F. Tittley P. Fuller V. ( 1987) Electroblotting and immunohistochemical staining for identification of platelet antibodies. British Journal of Haematology, 67, 437 441.
13. Rock G. Mackenzie A. Hashemie S. ( 1988) Verotoxin-induced release of vWF and production of tissue factor by human endothelial cells. Blood, 72, 308a.
14. Rock G. Chauhan K. Jamieson G.A. Tandon N.N. ( 1994) Anti-CD36 antibodies in patients with lupus anticoagulant and thrombotic complications. British Journal of Haematology, 88, 878 880.
15. Rowe P.C. Orrbine E. Loir H. Well G.A. McLaine P.N. ( 1993) A prospective study of exposure to verotoxin-producing Escherichia coli among Canadian children with haemolytic uraemic syndrome. Epidemiology and Infection, 110, 1 7.
16. Tandon N.N. Ockenhours C.G. Greco N.J. Jamieson G.A. ( 1991) Adhesive functions of platelets lacking GPIV (CD36). Blood, 78, 2809 2813.
17. Tandon N.N. Rock G. Jamieson G.A. ( 1994) Anti-CD36 antibodies in thrombotic thrombocytopenic purpura. British Journal of Haematology, 88, 816 825.
18. Tarr P.I. Gordon C.A. Chandler W.L. ( 2005) Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet, 365, 1073 1086.
19. Trezzini C. Jungi T.W. Spyche M.O. Maly F.E. Rao P. ( 1990) Human monocytes CD36 and CD16 are signaling molecules. Evidence from studies using antibody-induced chemiluminescence as a tool to probe signal transduction. Immunology, 71, 29 37.
20. Tsai H.M. Lian E.C.Y. ( 1998) Antibodies to Von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. The New England Journal of Medicine, 339, 1585 1594.